134 Phase 2 clinical trials of NA-931 to study subjects who are obese with at least one weight-related comorbid condition L.L
How can these takeaways inform the efficacy of novel drug development efforts in 2023
GSH was shown to be the main inhibitor in the active site of the main protease (M pro ), the essential protein for virus invasion, and cysteine (Cys300) glutathionylation inhibits M pro activity by blocking its dimerization supporting the use of GSH in COVID-19 patients (Davis et al., 2021
Dont take two doses to make up for a missed dose
The mechanism works the same way whether a patient has elevated blood sugar or maintains normal glucose levels, making these drugs equally relevant for weight management across metabolic profiles
Whiteman M, Gooding KM, Whatmore JL, Ball CI, Mawson D, Skinner K, et al